Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Cancer Diagnosis and Treatment · Head and Neck Cancer Studies
Correction **: ** BMC Cancer 24, 430 (2024)
https://doi.org/10.1186/s12885-024-12155-3
Following publication of the original article [1], the authors noticed that Fig. 4 was a duplicate of Fig. 3.
This correction article consists of the correct Fig. 3 and Fig. 4. Fig. 33A, PFS according to PD-L1 CPS classes; 3B, OS according to PD-L1 CPS classes; 3C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3E, PFS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes; 3F, OS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classesFig. 44A, PFS according to ECOG PS classes; 4B, OS according to ECOG PS classes; 4C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4E, PFS in patients treated with pembrolizumab monotherapy according to ECOG PS classes; 4F, OS in patients treated with pembrolizumab monotherapy according to ECOG PS classes
The original article [1] has been corrected.
The reference list from the paper itself. Each links out to its DOI / PubMed record.